Skip to content
Publications
Migraine Manuscripts
- Shrewsbury, S., Kori, S., Miller, D., Pedinoff, A. and Weinstein, S. “Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics” Curr Med Res Opin 2008; 24(7):1977-1985.
- Shrewsbury, S., Cook, R., Talor, G., Edwards, C., Ramadan, N. “Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered Via a Novel (TEMPO™) Inhaler” Headache 2008, 48:355-367.
- Shrewsbury SB, Stonerook M, Okikawa JK. “Intrapulmonary and intravenous administrations of DHE have similar CV effects in the conscious dog” Br J Pharmacol. PMID – 18289809 [PubMed – in process] 2008 May 26; 154(6):1254-1265.
Migraine Posters
- Novel Aerosol Delivery of Ergotamine Tartrate via Tempo® Inhaler in Humans [609KB]
As presented at the American Academy of Neurology (AAN) 58th Annual Meeting, April 2006
- MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE [88KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Pharmacological Profiling of Dihydroergotamine and its Relevance to Systemic Delivery via the Respiratory Tract [142KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom over 24 and 48 Hours Post Dosing [68KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo® Inhaler [108KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo® Inhaler [79KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Chronic Inhalation Toxicity Assessment of Dihydroergotamine in Dogs [142KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
- Dihydroergotamine Mesylate Monohydrate Solid State Characterization for Inhalation Formulation: Polymorph Screening and Determination of Amorphous Content [362KB]
As presented at the Respiratory Drug Delivery Conference (RDD), May 2008
- Precision Dosing of Dihydroergotamine (DHE) by Inhalation [603KB PDF]
As presented at the 13th Congress of the International Headache Society, June 2007
- Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo® Inhaler) [1067KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
- Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel System (Tempo® Inhaler) [3746KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
- Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo® Inhaler) [3937KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
- Delivery Performance of Dihydroergotamine Mesylate (DHE) Using the Breath Synchronized, Plume Controlled Tempo® Inhaler [455KB PDF]
As presented at the Respiratory Drug Delivery (RDD X) Conference, April 2006
- Intra-pulmonary Artery as Compared to Peripheral Venous Dosing of Dihydroergotamine (DHE) in Telemeterized, Awake Dogs [219KB PDF]
As presented at the American Academy of Neurology (AAN) 58th Annual Meeting, April 2006